Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study

BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial cytokine implicated in asthma pathogenesis, from binding to its heterodimeric receptor. In the phase 2b PATHWAY study, tezepelumab significantly reduced annualized asthma exacerbation rates...

Descripción completa

Detalles Bibliográficos
Autores principales: Emson, Claire, Corren, Jonathan, Sałapa, Kinga, Hellqvist, Åsa, Parnes, Jane R, Colice, Gene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868291/
https://www.ncbi.nlm.nih.gov/pubmed/33568920
http://dx.doi.org/10.2147/JAA.S288260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868291/
https://www.ncbi.nlm.nih.gov/pubmed/33568920
http://dx.doi.org/10.2147/JAA.S288260

Ejemplares similares